Bergua Burgués, Juan Miguel | Hematología y Hemoterapia |

Resultados: 177
Tipo Título / Nombre Autor(es) Año
Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma Tilly H, Morschhauser F, Sehn LH, Friedberg JW, Trneny M..., Bergua-Burgués JM 2021
The POLARIX Study: Polatuzumab Vedotin with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma Morschhauser F, Sehn LH, Friedberg JW, Trneny S ..., Bergua Burgues JM 2021
Long-Term Subgroup Analyses from Azacitidine Vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid Leukemia Patients: Results from the Pethema Registry Labrador J, Fuente A de la, Martínez-Cuadrón D, Rodríguez-Veiga R..., Bergua Burgues JM 2021
Patterns of Salvage Therapy in Patients with Acute Myeloid Leukemia Treated Upfront with Azacitidine or Decitabine: Results from the Pethema AML Registry Labrador J, Fuente A de la, Martínez-Cuadrón D, Rodríguez-Veiga R..., Bergua Burgues JM 2021
Integrated Multidimensional Flow Cytometry (MFC) and Next-Generation Sequencing (NGS) to Reconstruct Evolutionary Paterns from Dysplasia to Acute Myeloid Leukemia (AML) Simoes CP, Chillon C, Martínez -Cuadrón D, Calasanz JM..., Bergua Burgues JM 2021
First-Mind: Primary Analysis from a Phase Ib, Open-Label, Randomized Study to Assess Safety of Tafasitamab or Tafasitamab + Lenalidomide in Addition to R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma Belada D, Kopeckova K, Bergua Burgues JM, Stevens D 2021
Characteristics and Outcome of Patients with Acute Myeloid Leukemia and Trisomy 4 Kayser S, Martínez-Cuadrón D, Hanoun M, Stölzel F..., Bergua JM 2021
Nationwide Laboratory Network for AML Cross-Validated NGS Studies: Results from a Real-Life Cohort of the Pethema Group Sargas C, Ayala R, Cillon C, Larrayoz MJ..., Bergua JM 2021
Long-Term Survival after Intensive Chemotherapy or Hypomethylating Agents in AML Patients Aged 70 Years and Older: A Large Patient Data Set Study from Dataml, SAL and Pethema European Registries Recher C, Rolling C, Berard E, Bertoli S..., Bergua JM 2021
Treatment patterns and outcomes of 2310 patients with secondary acute myeloid leukemia: a PETHEMA registry study Martínez-Cuadrón D, Megías-Vericat JE, Serrano J, Martínez-Sánchez P, Rodríguez-Arbolí E..., Bergua Burgués JM 2021